Nuclera
Biotech · United Kingdom · private
Nuclera built a benchtop machine that screens and prints purified proteins in about 24 hours, and extended its Series C to $87m in January 2026 to add full antibody expression and binding validation.
The record
0 figures · 2 rounds · 10 backers · 3 feed items
Every one of them carries its source, its date, and its age when it has one. Reading the record takes a free account; the account is how you keep a watchlist.